Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
6 studies found for:    cholangiocarcinoma AND amsterdam type | Open Studies
Show Display Options
Rank Status Study
1 Unknown  Quality of Life in Patients With Unresectable Hilar Cholangiocarcinoma on Palliative Metallic Stent Versus Plastic Stent
Condition: Unresectable Hilar Cholangiocarcinoma
Intervention: Device: biliary stent
2 Recruiting Second Line Chemotherapy FOLFIRINOX in Irresectable Cholangiocarcinoma
Condition: Cholangiocarcinoma
Intervention: Drug: FOLFIRINOX
3 Recruiting Metformin And Chloroquine in IDH1/2-mutated Solid Tumors
Conditions: Glioma;   Cholangiocarcinoma;   Chondrosarcoma
Intervention: Drug: Metformin and chloroquine combination
4 Recruiting Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Conditions: Breast Cancer;   Cholangiocarcinoma;   Colorectal Cancer;   Head and Neck Neoplasms;   Lymphoma, Large-Cell, Anaplastic;   Melanoma;   Neuroendocrine Tumors;   Non-Small Cell Lung Cancer;   Ovarian Cancer;   Pancreatic Cancer;   Papillary Thyroid Cancer;   Primary Brain Tumors;   Renal Cell Carcinoma;   Sarcomas;   Salivary Gland Cancers;   Adult Solid Tumor
Intervention: Drug: Entrectinib
5 Not yet recruiting SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma
Condition: Intrahepatic Cholangiocarcinoma
Interventions: Drug: Cisplatin-gemcitabine;   Device: Radiation: SIRT + chemotherapy (cisplatin-gemcitabine)
6 Recruiting Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Observation After Curative Intent Resection of Biliary Tract Cancer
Conditions: Cholangiocarcinoma;   Gall Bladder Carcinoma
Interventions: Drug: Gemcitabine;   Drug: Cisplatin;   Other: Observation

Indicates status has not been verified in more than two years